Oxaloacetate in Myasthenia Gravis

Summary

This is a phase 1 clinical trial studying whether or not oxaloacetate has a positive effect on patients with Myasthenia Gravis. Patients will be assigned to one of three cohorts which will determine the dose of oxaloacetate they will be given. Subjects will take the study drug for 4 weeks and be on placebo for 4 weeks.

Timeline

Start

2025-08

Primary completion

2026-08

Completion

2026-12

Outcome

Outcome not reported

Stopped (Business): “No funding”

Drugs

Indications